B-cell non-Hodgkin lymphoma

This study looks at how well the drug glofitamab works in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are tracking how many patients achieve a complete response after receiving glofitamab through a compassionate use p…

This early-stage trial tests an experimental oral drug called DZD8586 in adults with B-cell Non-Hodgkin lymphoma that has returned or stopped responding to standard treatments. The study aims to find a safe dose and check whether the drug can shrink tumors. Participants take the …

This early-stage trial is testing a new treatment called ACE1831 for adults with B-cell lymphoma that has come back or not responded to at least two prior treatments. ACE1831 uses immune cells from healthy donors that are modified to target and kill cancer cells. The study aims t…

This phase 2 trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or combined with idelalisib or ibrutinib in 65 patients with chronic lymphocytic leukemia (CLL) or low-grade B-cell non-Hodgkin lymphoma (NHL) that had returned or stopped responding to treatment. The…

This phase 2 trial tested a combination of two treatments—CD19/22 CAR-T cells (a type of immune cell therapy) and tislelizumab (a PD-1 inhibitor that helps immune cells attack cancer)—in 18 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal was to see if t…

This completed study tested a two-step approach for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by CAR-T cell therapy. The goal was to see if this combination could improve how l…

This study tested a new combination treatment for people with a type of blood cancer (B-cell non-Hodgkin's lymphoma) that did not respond to standard therapies. The treatment combined a drug (XPO-1 inhibitor) with specially engineered immune cells (CAR-T cells). The goal was to s…

This early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …

This early-stage trial tested a new drug called INCB040093, alone or combined with itacitinib, in 121 adults with B-cell cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. Researchers also looked for sig…

This phase 1 trial tested a new therapy called CD22-CAR T cells in 134 children and young adults (ages 1-39) with B-cell leukemia or lymphoma that had not been cured by standard treatments. The therapy involves taking a patient's own white blood cells, modifying them in a lab to …

This study tested a treatment called KTE-X19, a type of CAR T-cell therapy, in 95 children and adolescents whose B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) had returned or stopped responding to standard treatments. The therapy involves collecti…

This study tested a new treatment called CTX131 for adults with certain blood cancers (T-cell lymphoma, B-cell lymphoma, or acute myeloid leukemia) that had returned or stopped responding to standard therapy. CTX131 uses a patient's own immune cells, modified with CRISPR gene edi…

This trial tested a new therapy called AB-101, made from natural killer (NK) cells, in 45 people with B-cell non-Hodgkin lymphoma that had come back or stopped responding to treatment. The study looked at AB-101 alone or combined with other drugs like rituximab or chemotherapy. T…

This study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from patients' own blood cells and safely given to adults with hard-to-treat B-cell leukemia or lymphoma. The main goals were to see if the cells could be produced successfully and…

This study tested a drug called glofitamab in 67 people with certain types of lymphoma (a blood cancer) that did not respond to or came back after CAR T-cell therapy. Participants received a pre-treatment followed by up to 11 cycles of glofitamab. The goal was to see if this anti…

This study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting wors…

This early-phase trial tested a new treatment called BZ019, made from a patient's own immune cells modified to attack cancer. It involved 12 adults with aggressive B-cell lymphomas that had not responded to standard therapy. The main goals were to check safety and see if the trea…

This early-stage trial tested a personalized cell therapy called CD19 CAR T cells in 20 adults with relapsed or refractory B-cell lymphoma. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack cancer cells, and infusing them back. T…

This phase 3 trial tested whether adding 6 doses of rituximab to standard chemotherapy improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. The study enrolled 482 high-risk patients aged 6 months to 18 years. The goal was to…

This study tested a new treatment called anti-CD19 CAR-T cell therapy for adults with B-cell blood cancers that returned or didn't respond to prior treatments. The therapy uses a patient's own immune cells, modified in a lab to target and kill cancer cells. 58 adults received the…

This phase 2 study tested an oral drug called pirtobrutinib in 87 Chinese adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma who had already received standard treatments. The goal was to see how well the drug shrank tumors and to check f…

This early-phase study tested a new cell therapy called C-CAR039 in 3 adults with B-cell non-Hodgkin's lymphoma that had come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target two proteins (CD19 and CD20) on cancer cells. T…

This early-stage trial tested a new oral drug, JNJ-64619178, in 114 people with advanced cancers (including solid tumors, lymphoma, and myelodysplastic syndromes) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effect…

This study tested a new radiation schedule (once a week for 5 weeks) in 10 people with B-cell lymphoma that came back or didn't respond to treatment. The goal was to see if this schedule is practical and reduces side effects before patients receive CAR T-cell therapy. The approac…

This phase 2 trial tested whether anakinra, a drug normally used for rheumatoid arthritis, can prevent two serious side effects of CAR-T cell therapy: cytokine release syndrome (CRS) and nerve damage. The study enrolled 27 adults with B-cell non-Hodgkin lymphoma who were receivin…

This early-stage trial tested a new drug called JNJ-75348780 in 147 people with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals were to check safe…

This early-phase trial tested a drug called odronextamab in 200 people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that had stopped responding to prior treatments. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to kill …

This phase 1/2 trial tested a new treatment for people with CD30-positive Hodgkin or non-Hodgkin lymphomas that returned or didn't respond to prior therapy. The treatment combines AFM13, an antibody that targets cancer cells, with natural killer (NK) cells from donated umbilical …

This early-phase trial tested an experimental drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to prior treatments. The main goals were to find a safe dose and check for side effects. The study is complete, but it is …

This study tests a drug called mosunetuzumab, given alone or with another drug (atezolizumab), in people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to treatment. The goal is to find the best dose and check safety and effec…

This study looked at medical records from over 2,700 people in Japan with a type of lymphoma (B-cell non-Hodgkin's lymphoma) who were treated with Rituximab Pfizer. The goal was to see how often infections and other side effects happened, and to compare these results with those f…